Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fungal alpha-1,3-glucan and alpha-1,6-glucan are essential polysaccharide components of the cell walls of various pathogenic fungi, including Aspergillus fumigatus, Histoplasma capsulatum, and Cryptococcus neoformans (Beauvais et al., 2001, Journal of Bacteriology). Alpha-1,3-glucan, in particular, is a critical virulence factor that provides structural support and facilitates immune evasion by masking beta-glucans from detection by host pattern recognition receptors like Dectin-1 (Rappleye et al., 2007, Science). Alpha-1,6-glucan linkages are also found in fungal cell wall structures, often as part of more complex glycan networks that contribute to the organism's environmental resilience and adherence (Fujiwara et al., 2022, Journal of Fungi). These alpha-glucans are synthesized by fungal-specific enzymes, such as alpha-1,3-glucan synthase (AGS), which are absent in mammalian hosts, making them promising targets for the development of highly selective antifungal agents (Marion et al., 2006, Molecular Microbiology). Although no drugs targeting these specific glucans are currently FDA-approved, they are being actively investigated as targets for small-molecule inhibitors, monoclonal antibodies, and carbohydrate-based vaccines (Stayer et al., 2020, Frontiers in Cellular and Infection Microbiology). Successful targeting of these molecules could lead to weakened fungal cell walls and enhanced host immune clearance, providing a novel approach to treating life-threatening invasive fungal infections.
Inhibition of fungal cell wall biosynthesis through the targeting of alpha-glucan synthase enzymes, or direct binding and neutralization of cell wall glucans by monoclonal antibodies to promote immune-mediated clearance.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fungal alpha-1,3-glucan and alpha-1,6-glucan.